<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> is essential to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development and progression, and its inhibition has been shown to benefit patients with several different <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A considerable number of antiangiogenic compounds have been evaluated for the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but only bevacizumab and aflibercept were able to demonstrate a survival benefit in phase III trials </plain></SENT>
<SENT sid="2" pm="."><plain>In this review, we discuss important aspects of the interrelationship between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and the microenvironment leading to <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e>, with a focus on <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical data on antiangiogenic therapies for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in the metastatic and adjuvant settings, as well as the potential use of antiangiogenics beyond <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> are analyzed </plain></SENT>
<SENT sid="4" pm="."><plain>The need to identify surrogate biomarkers towards a more personalized approach in <z:hpo ids='HP_0002664'>oncology</z:hpo> is emphasized as this is becoming increasingly important in drug development </plain></SENT>
</text></document>